

WE WORK TOGETHER

WE ARE
MACMILLAN
CANCER SUPPORT

NAEDI, NICE and CA125

Dr Richard Fisher, Macmillan GP

The NICE guidelines for Ovarian Cancer of April 2011 included CA125 testing followed by USS of abdomen and pelvis as part of a 'risk malignancy index' (RMI).

Is this a path followed by GPs in the real world?

Did the result of CA125 test make any difference in diagnosing or excluding an ovarian cancer or the tests requested?

The pathology lab at the Great Western Hospital, Swindon, supplied CA125 results and NHS number for approximately 200 patients who had this test in January, February and March in 2011, 2012 and 2013.


This was before the NICE guidelines, a year after and during the recent local NAEDI campaign highlighting the symptoms of ovarian cancer.

The local Macmillan GP, gynae-oncology consultant and pathologist devised a short survey for the test.

They requested GPs to complete - and were looking at the symptoms, signs, examination or other tests undertaken and any onward referral made for all 200 patients.

One real benefit was the increased co-operation and interest of both primary and secondary care in the early diagnosis of cancer.

What do you think the results showed?



Lift up

WE SHARE KNOWLEDGE